FDA extends review of Somaxon's Silenor for insomnia
This article was originally published in Scrip
Executive Summary
The US FDAhas notified Somaxon Pharmaceuticals that it will not be able to complete its review of the company's NDA for its lead insomnia drug candidate, Silenor, by its user fee date of December 1st and has extended the review by up to three months to February 28th, 2009.